Quick Facts

• Addresses: Symptoms related to estrogen deficiency after menopause.
• Key Relief: Helps with moderate to severe vasomotor symptoms (e.g., hot flashes).
• Skeletal Support: Contributes to the reduction of bone mineral loss in postmenopausal women with a high fracture risk.

---

What Femoston 2 / 10 Treats: Main Uses and Benefits

Femoston 2 / 10 is a specific type of hormone replacement regimen intended for use by postmenopausal women who still have their uterus. Its core function is to provide relief from a range of symptoms that manifest due to the decline in estrogen levels following menopause.

One primary therapeutic domain is the management of moderate to severe vasomotor symptoms. These expressions of estrogen deficiency commonly include recurrent hot flushes and episodes of profuse sweating.

In addition to symptom relief, this therapy also contributes to the prevention of postmenopausal bone mineral loss (osteoporosis) in women who present with an elevated risk of future skeletal fractures and who are not suitable candidates for other approved treatments for bone protection. The inclusion of dydrogesterone, a progestogen, in the regimen offers protection for the uterine lining against the proliferative influence of the estrogen component.

Treatment is typically initiated for symptoms that negatively impact quality of life and should continue only as long as the potential benefits outweigh the possible considerations, as advised by a healthcare professional.

Who Can and Cannot Use Femoston 2/10?

Femoston 2/10 is an official prescription medicine intended for a specific population and is subject to strict eligibility rules as defined in governmental regulatory documents.

Eligibility Requirements

Use of Femoston 2/10 is limited to postmenopausal women who are at least six months past their last menstrual period. Importantly, this combined product is specifically for women who have an intact uterus (meaning they have not had a hysterectomy), as the included progestogen component (dydrogesterone) is necessary to protect the uterine lining from the effects of the estrogen component (estradiol).

Contraindications (Who Must Not Use It)

The medicine is strictly contraindicated and must not be used by individuals with certain active or historical conditions. These include:

• A known, past, or suspected history of breast cancer or other estrogen/progestogen-dependent malignant tumors.
• Active liver disease or a history of liver disease where liver function has not returned to normal.
• Current or recent history of blood clots in the veins or arteries (thromboembolic disease) or known blood clotting disorders (thrombophilic states).
• Undiagnosed abnormal genital bleeding or untreated endometrial hyperplasia (excessive thickening of the womb lining).
• Known hypersensitivity to the active substances or any excipients.
• Pregnancy and lactation (breastfeeding) are also absolute contraindications for use.

Interactions with other medicines and products

The effectiveness of Femoston 2/10 may be reduced by certain medicines that are known to induce the metabolism of hormones, specifically through the Cytochrome P450 enzyme system in the liver. This effect can lower the concentration of estradiol and dydrogesterone in the body.

Medicinal Products that May Decrease Femoston Efficacy:

Category	Examples (Explicitly Listed)
Anticonvulsants	Phenytoin, Phenobarbital, Carbamazepine, Lamotrigine
Anti-infectives	Rifampicin, Ritonavir
Herbal Medicines	St John’s wort (Hypericum perforatum)

Co-administration with enzyme-inducing substances, particularly St John’s wort, is not recommended due to the potential for reduced therapeutic effect and altered bleeding profiles. If co-administration with enzyme inducers is necessary, increased clinical monitoring may be required.

Conversely, Femoston can interfere with the metabolism of other medicines, potentially leading to increased plasma concentrations of those drugs. This interaction is clinically significant for medicines with a narrow therapeutic index, such as Tacrolimus, Ciclosporin, Fentanyl, and Theophylline. For these medicines, careful monitoring and possible dosage adjustment by a healthcare professional are essential to avoid toxicity.

Femoston 2 / 10 contains 17beta-estradiol and dydrogesterone. The 17beta-estradiol component is a steroidal estrogen that functions as a high-affinity agonist for the nuclear estrogen receptors (ERs), specifically ERalpha and ERbeta.

Upon cellular entry and binding, the activated ER-ligand complex dimerizes and translocates to the nucleus. This complex then interacts with estrogen response elements (EREs) in the promoter regions of target genes, modulating gene transcription. This transcriptional control affects the synthesis of various proteins in target tissues like the hypothalamus, pituitary, bone, and reproductive tract.

The dydrogesterone component is a synthetic progestogen structurally related to progesterone. It acts as a selective agonist for the nuclear progesterone receptors (PRs), including PR-A and PR-B, without significant affinity for other steroid hormone receptors.

Similar to estradiol, activated PR-ligand complexes dimerize and bind to progesterone response elements (PREs), resulting in the transcriptional regulation of specific target genes. In endometrial cells, this progesterone signaling modulates the cellular environment that was previously stimulated by the estrogenic component, inducing secretory transformation and maturation of the endometrium, which subsequently leads to periodic shedding of the tissue.

Femoston 2 / 10 is an oral hormonal preparation administered as a continuous sequential regimen over a 28-day cycle. The official instructions specify taking one tablet daily to ensure constant administration without scheduled treatment breaks between packs, establishing the foundational use protocol. This usage is intended to utilize the lowest effective dose for the shortest required duration.

The administration is distinctly divided into two phases within the 28-day cycle. For the first 14 days, the daily tablet contains Estradiol 2 mg only. This is followed by the combined tablet, which contains Estradiol 2 mg and Dydrogesterone 10 mg, taken for the subsequent 14 days. The tablets must be swallowed whole with water, and while they can be taken with or without food, they should ideally be taken at the same time each day to support consistent plasma levels.

Procedural Rules for Proper Use

For administration, if a dose is forgotten, the procedural rule for correction is governed by a 12-hour threshold. If less than 12 hours have elapsed since the usual time, the forgotten tablet should be taken immediately. Conversely, if more than 12 hours have passed, the missed dose must be skipped, and the individual should continue with the next dose at the regular time, ensuring the correct sequential flow is maintained.

For initiation, administration may begin on any convenient day for new users, but individuals switching from another sequential HRT should begin the new pack the day after their prior regimen is complete. Regarding specific populations, official prescribing information notes that clinical experience is limited in treating women older than 65 years, and there is no relevant indication for use in the paediatric population.

Research Evidence / Overview of Studies for Femoston 2 / 10

Research Evidence for Vasomotor Symptoms (Hot Flushes and Sweats)

Research exploring how symptoms change over time was conducted primarily through short-term randomized controlled trials (RCTs) and systematic reviews. These studies examined the administration of the oral combination therapy, comparing it to a non-active treatment (placebo) in postmenopausal women. The research monitored patient-reported outcomes describing perceived discomfort, specifically measuring the frequency and intensity of hot flashes and night sweats using patient-reported outcomes.

Findings describe patterns observed in the studies where administering the combination therapy was evaluated for patterns related to changes in the measured frequency and severity of vasomotor symptoms. What remains uncertain is the long-term characterization of these outcomes. Follow-up durations were limited in many initial efficacy trials, meaning there is limited information for long-term outcomes regarding the sustained symptom patterns.

Research Evidence for Skeletal Support

This therapy was studied for its use in conditions marked by functional limitations related to bone loss. The research involves intermediate- to long-term RCTs and large observational cohort studies, examining the combination therapy's role in bone health for postmenopausal women identified as having an elevated risk of fracture. Outcomes related to systemic or functional imbalance, such as changes in Bone Mineral Density (BMD) at the hip and spine, were monitored, and the incidence of fractures was observed in the studied populations.

Observational evidence suggests an association between use of the combination and patterns of fracture incidence in studies observing responses over defined time intervals. Research indicates that this approach is typically evaluated in a secondary context for skeletal support. Data for women over the age of 65 remain insufficient, meaning the results apply only to the populations studied in the research.

Studies on Endometrial Protection and Uterine Lining

Studies explored the importance of the sequential addition of the dydrogesterone component in women who still have their uterus. The studies monitored outcomes related to systemic or functional imbalance, specifically looking at the incidence of endometrial overgrowth (hyperplasia) and patterns of bleeding or spotting. Findings describe patterns observed in the studies, consistently reporting that administering the progestogen component was associated with specific patterns of tissue change, as measured by markers of endometrial safety. The research is ongoing to fully establish long-term effects, particularly the cumulative risk patterns beyond five years.

Key Studies & References WHO-ATC Classification: G03FB08 (Dydrogesterone and estrogen)

How to Store and Dispose of Femoston 2/10

---

Storage Requirements

Official labeling defines specific conditions to maintain product stability and ensure safety. Femoston 2/10 should generally be stored in a cool, dry place where the temperature remains below 30°C. The tablets must be kept in the original blister pack and outer carton until use to preserve their integrity.

Critically, the medicine must be stored in a location that is out of the sight and reach of children.

Disposal Instructions

Used or expired Femoston 2/10 must not be disposed of via household waste or wastewater, as the product may pose a risk to the aquatic environment. Disposal must follow local requirements for pharmaceutical waste. This typically involves returning the unused or expired product to a pharmacist or a designated medicine collection point.